Prognostic value of intrinsic subtypes in HR+/HER2- breast cancer after CDK4/6 inhibitors

Francesco Schettini, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain, explores the prognostic and predictive significance of intrinsic subtypes in HR+/HER2- metastatic breast cancer after progression on CDK4/6 inhibitors and endocrine therapy. Subtype switching, often to less endocrine-sensitive HER2-enriched disease, was associated with poorer outcomes. Luminal A subtypes showed the best progression-free and overall survival, benefiting from endocrine-based therapies, while non-luminal subtypes performed better with chemotherapy. Tumor profiling at progression is, therefore, important to optimize treatment strategies. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.